Objectives: To describe the current literature on pain assessment and pain treatment for community-dwelling people with dementia.
| INTRODUCTION
The world's population is ageing, with the global population of people aged 65 years and older projected to grow from 901 million in 2015 to almost 2.1 billion by 2050. 1, 2 Aligned to this population rise is the increasing prevalence of dementia. In 2015, approximately 47 million people were living with dementia worldwide; this rate is projected to increase to 131 million by 2050. 3, 4 One common comorbidity associated with ageing is painful conditions (eg, musculoskeletal pain), 5 and it is estimated that approximately 50% of people with dementia have a painful condition, concordant to older adults without dementia. 6 Symptoms associated with dementia (eg, diminished language capacity, memory impairment, and behavioural symptoms) may lead to difficulties articulating a pain experience. 7 Consequently, caregivers and clinicians may not recognise or interpret expressions of pain correctly and thus may inadequately assess and treat pain. 8 Poor pain management for people with dementia can cause adverse outcomes, such as neuropsychiatric symptoms, decreased quality of life, increased caregiver burden, and avoidable institutionalisation. It can also result in adverse drug events such as confusion, falls, and opioid overdose. [9] [10] [11] [12] Research conducted in residential, palliative, and acute care settings show that people with dementia are often treated differently compared with those without dementia. [13] [14] [15] [16] [17] [18] [19] [20] Furthermore, recent randomised control trials within these settings provide evidence that a step-wise prescription of analgesics can lead to a reduction in a range of neuropsychiatric symptoms and mood syndromes. 21, 22 Whilst this evidence shows the benefits of assessment and treatment of pain in people with dementia, the focus of such research has been largely restricted to formal care settings (eg, nursing homes), as reflected in a number of existing systematic reviews [23] [24] [25] [26] [27] [28] [29] and a recent meta-review. 30 As a consequence, the evidence is almost exclusively based on people with high severity dementia (ie, those without verbal communication capacity), [26] [27] [28] and very little research into pain assessment and/or treatment has been conducted among community-dwelling populations. 29 This highlights a significant knowledge gap in understanding the needs of community-dwelling people with dementia; this population will have greater diversity in the capacity to self-report their pain, and differences may exist in proxy reports from informal caregivers compared with caregivers within formal settings who may have professional training in assessment. Given that upward of 60% of people with dementia reside within community settings in the United Kingdom, 31 this is a pressing concern.
This review aims to describe the current literature on pain assessment and pain treatment for community-dwelling people with dementia. Specific objectives are to (1) synthesise the evidence on the use of pain assessment tools and methods and assess their utility within community-dwelling people with dementia and (2) synthesise the evidence on the use of pain treatments and evidence of efficacy for community-dwelling people with dementia.
| METHODS

| Patient involvement
A patient and public involvement meeting was organised with caregivers of people with dementia during project development.
Caregivers shared their personal experiences of the complexity of pain assessment and management for their relative with dementia, reiterating the importance of systematically reviewing the evidence on pain assessment and pain treatment for community-dwelling people with dementia. Table S1 for the MEDLINE search strategy).
| Search strategy
Searches were designed and conducted by L.B. with agreement and oversight from P.C., J.B., and J.J. (research information specialist). No search limits were applied for study design, date, or language of publication. Further supplementary searches were conducted in Google Scholar, and all reference lists of all included papers were hand screened. A citation search of all included papers were tracked to ascertain subsequent potential publications, as well as a screen of all reference lists of relevant commentaries, literature reviews, and systematic reviews.
| Criteria for considering studies for this review
Inclusion
Key points
• Timely recognition of pain for people with dementia is important to ensure effective management and reduce adverse effects of medication.
• Clinicians should adopt a multidimensional approach to pain assessment including self-report assessments, pain history information, physical examination, informantbased ratings, and observation of pain behaviours.
• For patients with dementia, regular and structured medication reviews to assess the use, efficacy, and side effects of analgesic prescriptions are essential.
• Further high-quality, longitudinal research is essential to examine the management of pain and the most effective pain management strategies for community-dwelling people with dementia throughout the progression of disease.
• Study participants must have a confirmed diagnosis of dementia and reside in the community (including living alone at home, with informal caregivers at home, retirement communities, wardencontrolled housing, or assisted living).
31
• Studies examining the use of self-report, informant-report, and behavioural observation tools and methods of pain assessment.
32
• Studies examining the use of treatments for pain (including pharmacological and non-pharmacological treatments for pain).
• Studies evaluating the effectiveness of treatments for pain (both pharmacological and non-pharmacological) with a pain assessment tool.
• Full-text peer-reviewed scientific journal articles.
• Studies published in English or other languages translatable via colleagues at the Research Institute.
Exclusion
• Studies with participants with dementia in nursing home, palliative, or hospital settings. If a study includes participants with dementia living in a variety of residential settings (eg, nursing home and community), the study will be excluded if the results specific to people with dementia living in the community cannot be extracted independently.
• Studies solely focused on malignant pain. Cancer pain and its management is distinctly different from other common pain conditions.
Inclusion of papers involved a number of stages:
• Title screen to remove obviously irrelevant references (L.B.).
• Abstract screening and full-text screening (L.B.), with 20% of the abstracts and full texts screened independently by P.C. with good interrater agreement (greater than 95%). Discrepancies were resolved in discussion with a third reviewer (J.B.). 
| Data extraction
| Quality appraisal
Study quality was assessed using the National Institute of Health (NIH) Quality Assessment toolkit 33 for a number of study designs (case-control, observational cohort, cross-sectional, controlled intervention, and pre-post studies with no control group). Each tool consists of 11 to 14 items (dependent on design type), each evaluated as "yes," "no," or "not applicable/cannot decide" as guided by NIH guidance. Each item focused on the concepts, questions, and domains that are integral for the critical appraisal and evaluation of internal validity, including potential biases, confounding, and study power. Each item was used to guide the overall quality rating of "good," "fair," or "poor." A 20% sample of the studies were blind checked by P.C. to ensure consistency. Discrepancies were resolved in discussion with a third reviewer (J.B.).
| Analysis
Due to heterogeneity of the sample populations, settings, study designs, interventions, and reported outcomes, as well as a lack of statistical information to perform a meta-analysis, a narrative approach was adopted. The initial analysis stage assessed and described the quality of the included studies. Each study was assigned to the overarching theme or "cluster" 
| RESULTS
Searches identified 6741 unique records (up to October 2018), of which 129 were screened at full-text stage. One potentially eligible paper could not be obtained in full text. 35 Three additional papers were found through the supplementary searching, resulting in 32 studies included within the review (see Figure 1) . Of the included studies, 11 reported findings on pain assessment tools or methods (see Table 1 ), whereas 27 reported findings that explored treatments for pain (see Table 2 for an overview of pain treatment use and Table 3 for pain treatment effectiveness). Fifteen studies were conducted in North America, eight in Finland, two in Denmark, two in the United Kingdom, and one each in Canada, Sweden, France, Japan, and Italy.
| Quality assessment
Using the NIH Quality Assessment tools, four studies (12%) were assessed as good quality, 21 (66%) as fair quality, and seven (22%)
as poor quality.
Observational study designs were assessed using the NIH Quality Table S2 for detailed quality assessment).
| Pain assessment tools and methods
Eleven studies investigated pain assessment tools and methods for community-dwelling people with dementia. Five studies examined self-report pain tools, six studies examined informant-based ratings of pain, and one study examined a behavioural observation tool.
Only one study provided an overview of the frequency of pain assessment in primary care, 36 with pain assessment documented in 98% of patients' medical records. Of the pain assessments documented in this study, 98% used the Numerical Rating Scale (NRS), Visual Descriptor Scale (VDS), or Faces Pain Scale (FPS), whereas only 2% of medical records reported modifications of pain scales for cognitive impairment.
| Self-report
Four studies (one good quality, 37 one fair quality, 36 and two poor quality 38, 39 ) examined the utility of the FPS, Visual Analogue Scale (VAS), Pain Intensity Scale (PIS), 38, 39 and the Philadelphia Geriatric PIS. 36, 37 The completion rates of the FPS, VAS, and PIS were between 53%
and 67% for people with largely moderate to severe dementia (MiniMental State Examination [MMSE] of 15.6, ±5.9 SD; MMSE of 15.7, ±5.9 SD). 38, 39 Two studies considered the Philadelphia Geriatric PIS, and results show it was predictive of negative psychosocial events at 4 months follow-up 37 and identified a greater percentage of pain than reported in the medical records using the NRS, VDS, or FPS (94% vs 36%, respectively). 
| Informant pain ratings
In total, seven studies (four fair [40] [41] [42] [43] and three poor quality 39, 44, 45 ) investigated informant-pain ratings of pain for community-dwelling people with dementia using a variety of tools (VDS, 40, 43, 44 EQ 5D, 41, 42 the Philadelphia Geriatric PIS, 45 and FPS, VAS, and PIS
39
).
Five of these studies compared the percentage of self-reported and informant-reported pain for community-dwelling people with dementia. [40] [41] [42] [43] [44] Caregivers reported pain presence in the person with dementia more frequently than the person with dementia themselves (see Figure 2 ). In the three studies investigating the congruence between people with dementia and their caregiver's rating of pain, 
Abbreviations: AD, Alzheimer disease; CI, confidence interval; NSAID, non-steroidal inflammatory drugs; OR, odds ratio; PWD, people with dementia; USA, United States of America.
The control/reference group is community-dwelling people without dementia unless noted otherwise. However, for Haasum (2011), community-dwelling people without dementia ( a ) is labelled regardless for clarification between the multiple reference groups. 
| Observation of pain behaviours
One poor quality study investigated the Hospice Approach Discomfort Scale, a rating tool for observation of behaviours. 39 Such tools aim to identify pain using non-verbal cues (eg, behaviour, facial expression, and body language). 46 Poor correlations between the Hospice Approach Discomfort Scale and self-reported pain scales (FPS, VAS, and PIS) were reported; however, the author did not provide statistical evidence to support the findings, and therefore, estimations of concordance cannot be reported.
| Treatments for pain
Twenty-seven papers provided an overview of treatments for pain for community-dwelling people with dementia. Twenty-two papers (three good, [47] [48] [49] 16 fair, 19, 36, 40, 41, [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] and three poor quality 38, 44, 61 ) provided an overview of the pain treatments used by people with dementia.
| An overview of analgesic use
Two papers investigated the use of analgesics for community-dwelling people with dementia over time, irrespective of their analgesic potency. 47 included over-the-counter and prescribed paracetamol. Evidence suggests community-dwelling people with dementia use paracetamol more commonly than community-dwelling people without dementia. 19, 54 Longitudinal research suggests that the use of paracetamol increased from the first year after dementia diagnosis to 5 years post diagnosis. 47 
| Categories of analgesics prescribed
Nonsteroidal anti-inflammatory drugs (NSAIDs)
Across all studies, the combined prevalence of over-the-counter and prescribed NSAID use was 12% (range 5.9% to 21%). 19, 38, 40, 54 Lower rates of NSAID use 19 and prescriptions 54 were found for communitydwelling people with dementia compared with community-dwelling people without dementia (5.9% vs 12%, respectively) 19 and matched controls (13.2% vs 17.3%, respectively). 54 NSAID use decreased from the first year after dementia diagnosis to 5 years post diagnosis. 47 Additionally, the amount of NSAIDs prescribed during the first 180 days after index date (dementia diagnosis) also decreased each year from 2005 to 2011 for community-dwelling people with and without dementia, 54 suggesting a change in the practice of prescribing NSAID medication over time, irrespective of age and dementia progression. 
Opioids
The prevalence of opioid use for community-dwelling people with dementia was on average 13.8% (range 3.6% to 27.5%). 19, 38, 40, [48] [49] [50] [53] [54] [55] 57 Three studies (two fair quality 54, 55 and one good quality 48 )
show that community-dwelling people with dementia were prescribed less opioids than age, sex, and region of residence matched controls without dementia. However, two studies 19, 53 (both of fair quality)
showed that more community-dwelling people with dementia used 19 or were prescribed 53 opioid medication compared with communitydwelling people without dementia (see Figure 3 ).
The use of opioids for community-dwelling people with dementia was relatively consistent from the first year after dementia diagnosis to 5 years post diagnosis. 47 However, the amount of opioids pre- When opioid use was stratified further based on strength defined by the World Health Organisation's (WHO) Analgesic Ladder, an average 9.8% (range 2.7% to 16.8%) of people with dementia were prescribed weak opioids, whereas the proportion prescribed strong opioids was 5.3% (range 0.95 to 17.4%). 36, [53] [54] [55] The annual prevalence of strong opioid use was higher among community-dwelling people with dementia compared with the reference group. 53, 55 Community-dwelling people with dementia had a 1.44 higher odds of being prescribed fentanyl than matched controls 55 and two times higher odds than a comparison group without dementia. 53 Additionally, community-dwelling people with dementia had two times higher odds of being prescribed buprenorphine than community-dwelling people without dementia. 
| The effectiveness of treatments for pain
Five papers investigated the effectiveness of treatments for pain for community-dwelling people with dementia by measuring the result of an intervention upon pain assessment scores (one fair quality 63 and four poor quality 45, 61, 64, 65 ). Two papers investigated analgesic treatments 63, 64 with three investigating a non-pharmacological treatment/intervention for pain. 45, 61, 65 Elliot and Horgas 64 One study investigated the effectiveness of a nonpharmacological music intervention upon pain for this population. 65 Informal caregivers assessed pain 30 minutes before, during, and after listening to music. Many comparisons indicated non-significant findings; however, pain was significantly lower after listening to music than before listening to music. Two studies 45, 61 investigated the effectiveness of psychosocial interventions with mixed efficacy (see Table 3 ).
| DISCUSSION
This review provides an overview of the current evidence on both pain assessment and pain treatment for community-dwelling people with dementia. These two areas will be discussed in turn, contextualised by contrasting with comparative population groups and considering implications for practice, research, and policy.
| Pain assessment
The first aim of this review was to synthesise evidence on the use of pain assessment tools and methods and their utility for communitydwelling people with dementia. A large proportion of those who have moderate to severe dementia were unable to complete a self-report pain instrument, 38,39 suggesting a threshold effect for their efficacy in this population. Such findings are in line with the British Pain Society (BPS) recommendations that encourage the use of self-report measures for people with dementia (irrespective of their degree of FIGURE 3 Bar chart to illustrate the percentage of people with and without dementia prescribed/using opioid analgesic medication cognitive ability); however, certain adaptations (eg, simplified language and large fonts) may be required, especially for those with moderate and severe cognitive impairment. 7, 66 Overall, whilst self-report pain assessments can be used in community-dwelling people with dementia, a reliance on self-report methods in isolation is not recommended, especially for people with moderate to severe dementia. ) are yet to be tested or validated within community-dwelling people with dementia.
This review identified only one, low-quality study examining a behavioural observation pain assessment tool, and the conclusions from this study suggest a poor correlation with self-report methods.
Previous reviews have evaluated behavioural observation pain tools for people with dementia residing in formal care settings. 26, 45, 72, 73 These reviews suggest that behavioural observation pain tools hold promise to identify pain for people with dementia (eg, PAINAD, PACSLAC, DOLOPLUS2, and ECPA). 45, 74 However, further psychometric development and testing is essential. 26, 46 Behavioural observation tools may be suitable for community-dwelling people with dementia; however, the lack of testing and development in this setting, as illuminated by this review, hinders the ability to provide definitive conclusions.
| Treatment of pain
In the second aim of this review, the synthesis of evidence on the use of pain treatments for community-dwelling people with dementia indicates that community-dwelling people with dementia had less or similar analgesic prescriptions than comparator groups. This mixed evidence may be explained by the varying health care organisation and funding models across each region (the United States, Finland, and Sweden). In nursing home settings, the large majority of evidence to date has found people with dementia are prescribed less pain medication than their matched controls. 14, 75, 76 When analgesic medications were stratified into therapeutic classifications, community-dwelling people with dementia more commonly used paracetamol compared with community-dwelling older adults without dementia, with similar findings also evident in nursing home settings. 6, 19, 20 The notable preference towards paracetamol is consistent with recommendations suggesting paracetamol as a firstline analgesic treatment. 23, 77 The recent focus of pain in people with dementia may have contributed to increased paracetamol use, as an attempt to provide adequate treatment for this vulnerable population.
This review found that NSAID prescribing is lower for people with dementia compared with those without a dementia diagnosis and that NSAID use decreased over time for people with dementia. The findings from this review reflect National Institute for Health and Care
Excellence (NICE) guidelines (2015) 78 that advise that NSAIDs should be prescribed with caution for older adults due to the associated risks of gastrointestinal bleeding/perforation, renal dysfunction, and cardiovascular events 79, 80 and only if alternative safer treatments have not provided sufficient pain relief. [81] [82] [83] Similar trends in NSAID use are also evident for people with dementia living nursing home settings. This review identified three studies 48, 54, 55 that found less community-dwelling people with dementia were prescribed opioids;
however, two studies 19, 53 found that more community-dwelling people with dementia used opioid medication compared with comparator groups without dementia. Differences between the studies may contribute to the unclear findings; opioid prescriptions were identified at the time of the research interview, 19 during a 6-month period of dementia diagnosis 54 or a 1-year period (during 2005). 55 A much larger percentage of opioid prescriptions were evident when the length of investigation increased to a 5-year period potentially because of cohort effects. 48 A recent systematic review investigating opioid use for people with dementia (irrespective of residential status)
found that they used less opioids than people without cognitive impairment. 85 High-quality research to further explore opioid use for community-dwelling people with dementia is essential to determine if the findings align to those found in other residential settings and to further understand the implications for effective management.
When opioid prescriptions were stratified into weak and strong opioids, this review found that fentanyl and buprenorphine were prescribed more commonly to people with dementia compared with matched controls. 48, 53, 54 In nursing home settings, research suggests that older adults with cognitive impairment were more likely to receive fentanyl transdermal patch formulations as a first-line treatment for pain. 86, 87 Fentanyl and buprenorphine may be favoured for people with dementia due to the benefits of transdermal patch formulations for those with swallowing difficulties, impaired gastrointestinal function, and/or a reduced analgesic compliance. 85, 88 Finally, this review aimed to evaluate the effectiveness of pharmacological and non-pharmacological treatments; however, evidence was limited and low quality. Scheduled paracetamol treatment reduced pain scores for people with dementia. Such findings are comparable with larger trials conducting in nursing home settings. 21, 22 Additionally, experimental evidence suggests people with dementia may require more analgesia to reach the appropriate level of pain relief, questioning the current efficacy of analgesic treatment for people with dementia based on routine prescribing regimes 63 ; however, more research is essential prior to confirm this finding. This review identified only poor quality papers investigated the efficacy of non-pharmacological treatments (including music and psychosocial interventions) for pain in community-dwelling people with dementia. Other systematic reviews report that non-pharmacological treatments (eg, music therapy, Reiki, reflexology, and person-centred showering or bathing) can be effective in reducing pain for people with dementia living in formal care. 89 
| Strengths and limitations
This review has notable strengths. It is the first to provide a broad overview of the evidence on pain assessment and treatment for pain for community-dwelling people with dementia. The search strategy developed in collaboration with experienced information specialists is comprehensive with extensive supplementary searches. This review reports on the quality of evidence from the included studies, which has highlighted a low level of quality evidence on this topic within community-dwelling populations of those with dementia.
There are, however, limitations that are important to consider. Some studies [90] [91] [92] [93] [94] [95] provided information on pain assessment or pain treatment for people with cognitive impairment, using standardised instruments such as the MMSE; however, these studies did not provide sufficient information to confirm that participants had a diagnosis of dementia and were therefore not included in the review. Finally, the conclusions of this review need to be contextualised within the limited research to date; 12 studies actively recruited participants with mild to moderate, or newly diagnosed dementias, with many more recruiting an insufficient number of participants with severe dementia. Therefore, the extent of evidence on more severely affected community-dwelling people with dementia is limited, and more evidence is required in this subpopulation.
| Clinical implications
Due to the minimal high-quality research to date, this review was unable to provide definitive conclusions regarding a pain assessment tool or method to recommend for use with community-dwelling people with dementia. Clinicians should therefore adopt a multidimensional approach using "a hierarchy of pain assessment techniques" including self-report assessments, pain history information, physical examinations, informant-based ratings, and observation of pain behaviours, in line with previous recommendations. 96 Reliance on one method alone may lead to suboptimal assessment and treatment.
In terms of analgesic use, adverse effects, comorbidities, and polypharmacy are common in older adults, with the added complexity of cognitive impairments associated with dementia and the already outlined challenges in pain assessment. Due to these complexities, regular and structured medication reviews are needed to assess the use, efficacy, and side-effects of analgesic prescriptions, especially so as changes to cognitive ability are evident over the course of the disease. Care is particularly needed when new medications, such as transdermal analgesics are initiated to balance the risk of adverse drug reactions against the ease of transdermal patch administration of opioids. In conjunction with pharmacological strategies, prescribing clinicians should consider the use of nonpharmacological strategies to minimise drug-related adverse events.
| Research implications
In regard to pain assessment, research comparing multiple pain assessment instruments for a range of dementia severities using a clear and pre-defined protocol within a community sample is required. Highquality evidence is essential to assess the psychometric properties and clinical utility of pain assessment instruments (including self-and informant-based measures and behavioural observation pain tools)
for community-dwelling people with dementia.
Future research investigating treatments for pain should stratify analgesia by therapeutic classification, with a focus towards highquality longitudinal evidence to encompass the person with dementia's progression. Such evidence is essential to provide a basis for future randomised control trials, alike to those conducted in nursing home settings.
21,22,98
| CONCLUSIONS
This review identifies a dearth of high-quality studies exploring pain assessment and/or treatment for community-dwelling people with dementia, not least into non-pharmacological interventions. The consequences of this lack of evidence, given the current and projected prevalence of the disease, are very serious and require urgent redress.
In the meantime, clinicians should adopt a patient and caregiver centred, multi-dimensional, longitudinal approach to pain assessment and treatment in this population.
